First approved in 2017, Imfinzi was previously available in the U.S. as a combination therapy for treating metastatic NSCLC. More on AstraZeneca AstraZeneca PLC (AZN) Q2 2024 Earnings Call Transcript ...

AstraZeneca AZN announced that the FDA expanded the label of its blockbuster cancer drug Imfinzi for a fourth indication in lung cancer. The FDA approved Imfinzi in combination with platinum-based ...

April 5 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday its blockbuster cancer drug Imfinzi helped improve survival in patients in the early stages of an aggressive type of lung ...

References: Imfinzi ® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer. News release. AstraZeneca. June 17, 2024. https ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved by the Food and Drug Administration for the treatment of adult patients with resectable early-stage (IIA ...

BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and after surgery, improved survival rates in patients with bladder cancer, results that could reshape how muscle-invasive ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca's IMFINZI ® (durvalumab) in combination ...

The safety and effectiveness of IMFINZI has not been established in pediatric patients. NIAGARA is a randomized, open-label, multi-center, global Phase III trial evaluating perioperative IMFINZI ...

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.